Literature DB >> 1692948

Effects of low-dose nifedipine on a cold provocation test in patients with Raynaud's disease.

A Weber1, H Bounameaux.   

Abstract

The effects of 5 mg sublingual nifedipine on a standardized cold provocation test were compared with that of placebo in a double-blind, cross-over trial in 10 patients with Raynaud's disease. The percentage decrease of finger systolic pressure in the cooled finger (as compared with the contralateral control finger) was significantly lower at 10 degrees C (p less than 0.02) and 15 degrees C (p less than 0.05) after nifedipine than after placebo. These improved digital pressure values on cooling were associated with a decreased systolic blood pressure (SBP) from 131.2 (SD 10.8) to 126.2 (SD 10.1) mm Hg (p less than 0.001) and an increased heart rate (HR) from 65.5 (SD 16.1) to 69.6 (SD 16.7) beats/min (p less than 0.002) but without significant changes in diastolic blood pressure (DBP), digital blood flow (BF), or peripheral vascular resistance (PVR) in cutaneous vascular bed. Three patients experienced headache under nifedipine, but this side effect was disagreeable in only one case. These data suggest using low-dose nifedipine (5 mg sublingually) 15-30 min before predictable cold exposure and Raynaud's phenomenon. Such a procedure might be more effective and safer than chronic intake of higher doses of nifedipine, as currently recommended in Raynaud's attacks.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1692948     DOI: 10.1097/00005344-199005000-00023

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  2 in total

Review 1.  Quantifying digital vascular disease in patients with primary Raynaud's phenomenon and systemic sclerosis.

Authors:  A L Herrick; S Clark
Journal:  Ann Rheum Dis       Date:  1998-02       Impact factor: 19.103

Review 2.  Calcium channel blockers for primary Raynaud's phenomenon.

Authors:  Holly Ennis; Michael Hughes; Marina E Anderson; Jack Wilkinson; Ariane L Herrick
Journal:  Cochrane Database Syst Rev       Date:  2016-02-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.